✦ LIBER ✦

Measurement and treatment research to improve cognition in schizophrenia: neuropharmacological aspects

✍ Scribed by Mark A. Geyer; Carol A. Tamminga

Publisher: Springer
Year: 2004
Tongue: English
Weight: 66 KB
Volume: 174
Category: Article
ISSN: 0033-3158
DOI: 10.1007/s00213-004-1846-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

AVE1625, a cannabinoid CB1 receptor anta

AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents

✍ Mark D. Black; Rachel J. Stevens; Nancy Rogacki; Robert E. Featherstone; Yaw Sen 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 420 KB

Could HTR2A T102C and DRD3 Ser9Gly predi

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting

✍ Byungsu Kim; Eui Yul Choi; Chang Yoon Kim; Kyuyung Song; Yeon Ho Joo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB

## Abstract ## Objective This study seeks to replicate previous results indicating that T102C in the serotonin 2A receptor (HTR2A) and Ser9Gly in the dopamine D3 receptor (DRD3) were associated with a risperidone response to acutely exacerbated schizophrenia, and to determine whether possession of

Clinical improvement as reflected in mea

Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial

✍ Peter Tugwell; George Wells; Vibeke Strand; Andreas Maetzel; Claire Bombardier; 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB 👁 2 views